Literature DB >> 27190322

Eradication Strategies for Chronic Hepatitis B Infection.

Eleanor M P Wilson1, Lydia Tang1, Shyam Kottilil1.   

Abstract

Chronic hepatitis B infection affects >300 million people worldwide and is a leading cause of liver failure and cancer. Current approaches to treatment for chronic hepatitis B involve suppression of hepatitis B virus (HBV) DNA with the use of nucleoside analogues. Chronic suppressive therapy rarely results in a "functional cure" or absence of detectable HBV DNA in plasma and loss of detectable hepatitis B surface antigen after cessation of therapy. The major obstacles to achieving a functional cure are the presence of covalently closed circular DNA and ineffective/exhaustive immune system. This review focuses on novel approaches to target viral life cycle and host immunity to achieve a functional cure. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  HBV; eradication; exhaustion

Mesh:

Substances:

Year:  2016        PMID: 27190322      PMCID: PMC4889898          DOI: 10.1093/cid/ciw044

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  56 in total

Review 1.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 2.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Kenneth Kar-Lung Yan; Angel Mei-Ling Chim; Hoi-Yun Chan; Chi-Hang Tse; Paul Cheung-Lung Choi; Anthony Wing-Hung Chan; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

Review 4.  Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

Authors:  Robert G Gish; Man-Fung Yuen; Henry Lik Yuen Chan; Bruce D Given; Ching-Lung Lai; Stephen A Locarnini; Johnson Y N Lau; Christine I Wooddell; Thomas Schluep; David L Lewis
Journal:  Antiviral Res       Date:  2015-06-27       Impact factor: 5.970

Review 5.  Induced immunity against hepatitis B virus.

Authors:  Zeinab Nabil Ahmed Said; Kouka Saadeldin Abdelwahab
Journal:  World J Hepatol       Date:  2015-06-28

Review 6.  Host-virus interactions in hepatitis B virus infection.

Authors:  Luca G Guidotti; Masanori Isogawa; Francis V Chisari
Journal:  Curr Opin Immunol       Date:  2015-07-15       Impact factor: 7.486

7.  The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.

Authors:  Gaëtan Billioud; Christian Pichoud; Gerhard Puerstinger; Johan Neyts; Fabien Zoulim
Journal:  Antiviral Res       Date:  2011-08-18       Impact factor: 5.970

8.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

9.  HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells.

Authors:  Yongfen Xu; Yunwen Hu; Bisheng Shi; Xiaonan Zhang; Jiefei Wang; Zhanqing Zhang; Fang Shen; Qin Zhang; Shuhui Sun; Zhenghong Yuan
Journal:  Mol Immunol       Date:  2009-06-05       Impact factor: 4.407

10.  AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication.

Authors:  Nicholas D Weber; Daniel Stone; Ruth Hall Sedlak; Harshana S De Silva Feelixge; Pavitra Roychoudhury; Joshua T Schiffer; Martine Aubert; Keith R Jerome
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

View more
  5 in total

Review 1.  Elimination of Vertical Transmission of Hepatitis B in Africa: A Review of Available Tools and New Opportunities.

Authors:  Jodie Dionne-Odom; Basile Njei; Alan T N Tita
Journal:  Clin Ther       Date:  2018-07-05       Impact factor: 3.393

Review 2.  Drugs in Development for Hepatitis B.

Authors:  Altaf Dawood; Syed Abdul Basit; Mahendran Jayaraj; Robert G Gish
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

3.  Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.

Authors:  Sang Hoon Ahn; Patrick Marcellin; Xiaoli Ma; Florin A Caruntu; Won Young Tak; Magdy Elkhashab; Wan-Long Chuang; Fehmi Tabak; Rajiv Mehta; Jörg Petersen; William Guyer; Belinda Jump; Alain Chan; Mani Subramanian; Gerald Crans; Scott Fung; Maria Buti; Giovanni B Gaeta; Aric J Hui; George Papatheodoridis; Robert Flisiak; Henry L Y Chan
Journal:  Dig Dis Sci       Date:  2018-08-22       Impact factor: 3.199

Review 4.  Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?

Authors:  Ganesh Selvaraj Duraisamy; Dattatry Bhosale; Ivana Lipenská; Ivana Huvarova; Daniel Růžek; Marc P Windisch; Andrew D Miller
Journal:  Viruses       Date:  2020-09-07       Impact factor: 5.048

5.  Secular Trends of Acute Viral Hepatitis Incidence and Mortality in China, 1990 to 2019 and Its Prediction to 2030: The Global Burden of Disease Study 2019.

Authors:  Xing Su; Lin Zheng; Huami Zhang; Ting Shen; Yingna Liu; Xiaowei Hu
Journal:  Front Med (Lausanne)       Date:  2022-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.